Detaillierte Beitrags-Information

Zurück zur Liste

Beitragstitel Platelet concentrates for the treatment of rotator cuff tears
Beitragscode P09
  1. Raphael Blunier Vortragender
  2. Marvin Lucas Frommer Inselspital Bern
  3. Matthias A. Zumstein Shoulder, Elbow and Orthopaedic Sports Medicine, Sonnenhof Orthopaedics, Bern, Switzerland
  4. Michael Schär Inselspital Bern, Universität Bern
Präsentationsform Poster
  • A01 - Schulter/Ellbogen
Abstract Background: Despite improving surgical
techniques for rotator cuff repair, the retear
rate is still high at 26%. That is the reason why
nowadays we try to improve healing with
biological augmentation, i.e., with platelet
concentrates. Beside the easy production of
those autologous concentrates, the regulator
barriers are quite low. The timely use of
those products immediately after the blood
collection is a further advantage of platelet
concentrates. The term platelet concentrates
represents a large inhomogeneous group of
different concentrates with various properties.
Due to different manufacturing processes, not
every platelet concentrate product has the
same properties.
Objectives: Can the use of platelet concen-
trates in rotator cuff tears improve outcome?
How different is the outcome between the
different products?
Materials and methods: Through PubMed
we assessed 26 studies from 2007–2020.
Results and conclusion: The evaluation of
the studies which are currently available
shows that only P-PRP (leucocyte poor
platelet rich plasma) can be suggested for
the augmentation of rotator cuff repair. In
some studies, significant lower retear rates
for the P-PRP group were reported. However,
the results are heterogeneous. This puts the
benefit of P-PRP into perspective. Platelet
concentrates did not improve healing or the
clinical outcome after conservative therapies
of partial ruptures and tendinopathies.